Table 6.
Incremental cost-effectiveness ratios—cost per QALY
| Cost (£) | QALYs | Incremental cost (£) |
Incremental QALYs |
Incremental cost-effectiveness ratio (£/QALY) |
|
|---|---|---|---|---|---|
| Comparison excluding oxcarbazepine | |||||
| Carbamazepine | 1226 | 1·477 | .. | .. | .. |
| Topiramate | 2009 | 1·501 | 783 | 0·024 | Extended dominance |
| Lamotrigine | 2257 | 1·564 | 248 | 0·063 | 11851 |
| Gabapentin | 2561 | 1·491 | 304 | −0·073 | Dominated |
| Comparison including oxcarbazepine | |||||
| Carbamazepine | 1095 | 1·491 | .. | .. | .. |
| Oxcarbazepine | 1839 | 1·611 | 744 | 0·12 | 6200 |
| Topiramate | 1930 | 1·541 | 91 | −0·07 | Dominated |
| Lamotrigine | 2078 | 1·563 | 148 | 0·022 | Extended dominance |
| Gabapentin | 2573 | 1·480 | 495 | −0·083 | Dominated |